IL33 and systemic lupus erythematosus: Anti-IL-33 treatment significantly reduced mouse mortality, serum anti-dsDNA levels, renal damage, and circulating immune complexes in an MRL/Lpr mouse model, likely by promoting the expansion of Treg cells and MDSCs while decreasing expression of the pro-inflammatory cytokines IL-1β, IL-6, and IL-17 [183], which suggested a protective effect of IL-33 antagonization on SLE in mice.